B-421a-006 is a 24-month, double-masked, randomized, sham-controlled, multicenter study to evaluate the safety, tolerability, and efficacy of ultevursen in subjects with RP due to mutations in exon 13 of the USH2A gene.
B-421a-006 is a 24-month, double-masked, randomized, sham-controlled, multicenter study to evaluate the safety, tolerability, and efficacy of ultevursen in subjects with RP due to mutations in exon 13 of the USH2A gene.